2. Gene
  3. Src - SRC proto-oncogene, non-receptor tyrosine kinase Gene

Src - SRC proto-oncogene, non-receptor tyrosine kinase Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：SRC 原癌基因， 非受体酪氨酸激酶

种属: Rattus norvegicus

基因 ID: 83805 | 基因类型: protein coding

关于 Src

Primary_assembly 3: 146,091,841-146,139,476 forward strand.mRatBN7.2:CM026976.1

This gene has 2 transcripts (splice variants), 261 orthologues, 32 paralogues and is associated with 42 phenotypes. Biased expression in Brain (RPKM 86.6), Lung (RPKM 78.5) and 9 other tissues.

功能概要

该基因编码的蛋白可启动多种功能，包括雌激素受体结合活性；胰岛素受体结合活性；和蛋白质 C 末端结合活性。参与多个过程，包括细胞对脂质的反应；磷酸化的正调控；和信号转导的调节。位于caveola;神经元投射；和突触后密度。活跃于谷氨酸能突触和突触后特化，细胞内成分。用于研究帕金森症；脑缺血;高血压;癫痫持续状态；和 2 型糖尿病。该基因与结直肠癌相关的人类直系同源物（多个）；导管原位癌；前列腺癌;血小板减少症;和 2 型糖尿病。与人类 Src 同源（SRC 原癌基因，非受体酪氨酸激酶）。 [由基因组资源联盟提供，2022 年 4 月]

Enables several functions, including Estrogen Receptor binding activity; Insulin Receptor binding activity; and protein C-terminus binding activity. Involved in several processes, including cellular response to lipid; positive regulation of phosphorylation; and regulation of signal transduction. Located in caveola; neuron projection; and postsynaptic density. Is active in glutamatergic synapse and postsynaptic specialization, intracellular component. Used to study Parkinsonism; brain ischemia; hypertension; status epilepticus; and type 2 diabetes mellitus. Human ortholog(s) of this gene implicated in colorectal Cancer (multiple); ductal carcinoma in situ; prostate cancer; thrombocytopenia; and type 2 diabetes mellitus. Orthologous to human Src (Src proto-oncogene, non-receptor tyrosine kinase). [provided by Alliance of Genome Resources, Apr 2022]

Src 基因产物(1)

mRNA Protein Name
NM_031977.1 NP_114183.1 proto-oncogene tyrosine-protein kinase Src

Src 蛋白结构

SH3_Src

SH3_Src: cd12008 (87 - 148)

SH2_Src_Src

SH2_Src_Src: cd10365 (152 - 252)

PTKc_Src

PTKc_Src: cd05071 (265 - 541)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 500
  • 542 a.a.
蛋白主名 其他名称

proto-oncogene tyrosine-protein kinase Src

Rous sarcoma oncogene

c-Src

p60-Src

pp60c-src

proto-oncogene c-Src

tyrosine protein kinase c-src

tyrosine protein kinase pp60-c-src

v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog

v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog

相关产品

Approval
生物活性分子 (9)
目录号 产品名 作用方式
纯度 是否罕见病
HY-10181 Dasatinib Inhibitor 99.88% 是
HY-12047 Ponatinib Inhibitor 99.43% 是
HY-10158 Bosutinib Inhibitor 99.96% 是
HY-10209 Masitinib Inhibitor 99.98% 是
HY-10181A Dasatinib hydrochloride Inhibitor 98.86% 是
HY-108766 Ponatinib hydrochloride Inhibitor 99.55% 是
HY-10209A Masitinib mesylate Inhibitor 99.83% 是
HY-10181B Dasatinib monohydrate Inhibitor 98.48% 是
HY-10158A Bosutinib hydrate Inhibitor 99.87% 是
Clinical Phase
生物活性分子 (16)
目录号 产品名 作用方式
纯度 Phase
HY-10234 Saracatinib Inhibitor 99.92% Phase 3
HY-10340 Tirbanibulin Inhibitor 99.56% Phase 3
HY-10340A Tirbanibulin dihydrochloride Inhibitor 99.59% Phase 3
HY-10340B Tirbanibulin Mesylate Inhibitor 99.97% Phase 3
HY-13024 Rebastinib Inhibitor 99.91% Phase 2
HY-50868 Bafetinib Inhibitor 99.77% Phase 2
HY-32718 Pelitinib Inhibitor 98.80% Phase 2
HY-59047 Tolimidone Activator 99.89% Phase 2
HY-111787 Elzovantinib Inhibitor 99.97% Phase 2
HY-10987A ENMD-2076 Inhibitor 99.12% Phase 2
HY-10987 ENMD-2076 Tartrate Inhibitor 99.42% Phase 2
HY-10186 TG 100801 Inhibitor 98.60% Phase 2
HY-10187 TG 100801 Hydrochloride Inhibitor / Phase 2
HY-15749 XL228 Inhibitor 99.29% Phase 1
HY-112809 GSK2646264 Inhibitor 98.39% Phase 1
HY-112314 AZD0424 Inhibitor / Phase 1
Pre-clinical Phase
生物活性分子 (113)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-13805 PP2 Inhibitor 99.35% 否
HY-12299 WH-4-023 Inhibitor 99.75% 否
HY-15764A A 419259 trihydrochloride Inhibitor 99.21% 否
HY-12072 Lck Inhibitor Inhibitor 99.45% 否
HY-13804 PP1 Inhibitor 99.00% 否
HY-B0789 SU6656 Inhibitor 98.05% 否
HY-101053 Src Inhibitor 1 Inhibitor 99.96% 否
HY-13942 1-NM-PP1 Inhibitor 99.28% 否
HY-112096 eCF506 Inhibitor 99.30% 否
HY-136848 SM1-71 Inhibitor 96.00% 否
HY-13941 1-Naphthyl PP1 Inhibitor 99.08% 否
HY-N0752 Scutellarein Inhibitor 99.25% 否
HY-135299 CH6953755 Inhibitor 98.03% 否
HY-112852 TL02-59 Inhibitor 99.84% 否
HY-11011 A-770041 Inhibitor 99.95% 否
HY-130254 Src Inhibitor 3 Inhibitor 98.61% 否
HY-108318 RK-24466 Inhibitor 98.53% 否
HY-10395 PD173955 Inhibitor 99.12% 否
HY-W062835 CGP77675 Inhibitor 99.00% 否
HY-10372 PP121 Inhibitor 98.67% 否
HY-13561 AZM475271 Inhibitor 99.85% 否
HY-112182 UM-164 Inhibitor 99.15% 否
HY-P3279 EPQpYEEIPIYL Activator 98.94% 否
HY-15764 A 419259 Inhibitor 98.23% 否
HY-18303 AMG-47a Inhibitor 99.34% 否
HY-101963 AD80 Inhibitor 99.88% 否
HY-136605 DGY-06-116 Inhibitor 99.54% 否
HY-139147 iHCK-37 Inhibitor 99.69% 否
HY-155657 BT424 Inhibitor / 否
HY-78263 MNS Inhibitor 99.55% 否
HY-10644 Lck inhibitor 2 Inhibitor 99.81% 否
HY-10185 TG 100572 Hydrochloride Inhibitor 98.96% 否
HY-13941B 1-Naphthyl PP1 hydrochloride Inhibitor 99.94% 否
HY-P1377A Caffeic acid-pYEEIE TFA 98.50% 否
HY-120213 YH-306 Inhibitor 98.01% 否
HY-100434 PD-161570 Inhibitor 99.04% 否
HY-108485 Damnacanthal Inhibitor ≥98.0% 否
HY-18622 PP58 Inhibitor 99.75% 否
HY-107024 Osteogenic Growth Peptide (10-14) Inhibitor 99.69% 否
HY-108488 KB SRC 4 Inhibitor 99.66% 否
HY-127002 Squarunkin A Inhibitor 99.34% 否
HY-103274 PD180970 Inhibitor 99.27% 否
HY-153556 GW297361 Inhibitor 98.13% 否
HY-10181S Dasatinib-d8 Inhibitor 98.17% 否
HY-118144 PD166326 Inhibitor 99.99% 否
HY-125028 Hck-IN-1 Inhibitor 98.53% 否
HY-112345 PD-089828 Inhibitor 98.07% 否
HY-163144 DAS-5-oCRBN Degrader 98.08% 否
HY-N4201 β-Hydroxyisovalerylshikonin Inhibitor 99.83% 否
HY-132150A HPK1-IN-2 dihydrochloride Inhibitor 98.69% 否
HY-120595 JNJ-49095397 Inhibitor 99.85% 否
HY-W013857 Lavendustin C Inhibitor 98.32% 否
HY-N6596 7-Hydroxy-4H-chromen-4-one Inhibitor 99.94% 否
HY-N4127 3'-Demethylnobiletin 99.98% 否
HY-123506 Fenlean Inhibitor 99.56% 否
HY-122113 PD173952 Inhibitor 98.82% 否
HY-12047S Ponatinib-d8 Inhibitor 99.91% 否
HY-18237 KX1-004 Inhibitor 99.75% 否
HY-10158S Bosutinib-d8 Inhibitor ≥99.0% 否
HY-18507 AD57 Inhibitor 98.08% 否
HY-16905 T338C Src-IN-1 Inhibitor / 否
HY-16906 T338C Src-IN-2 Inhibitor / 否
HY-15764G A 419259 (GMP) Inhibitor / 否
HY-10184 TG 100572 Inhibitor / 否
HY-10234A Saracatinib difumarate Inhibitor 99.24% 是
HY-15324 PRT062607 acetate Inhibitor 99.83% 否
HY-112852A TL02-59 dihydrochloride Inhibitor / 否
HY-112291 SB 220025 Inhibitor / 否
HY-128397 CpCDPK1/TgCDPK1-IN-1 Inhibitor / 否
HY-163278 Lck-IN-2 Inhibitor / 否
HY-P1200A Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA Inhibitor / 否
HY-W062835A CGP77675 hydrate Inhibitor / 否
HY-W745090 Isomaltulose monohydrate Inhibitor / 否
HY-123298 Chrysotoxine Inhibitor / 否
HY-162413 (R)-LW-Srci-8 Inhibitor / 否
HY-112335 Lck Inhibitor III Inhibitor / 否
HY-P1111A Lyn peptide inhibitor TFA Inhibitor / 否
HY-115723 Antiallergic agent-1 Inhibitor / 否
HY-146014 Multi-kinase-IN-1 Inhibitor / 否
HY-P3773 p60c-src substrate II / 否
HY-12847 CCT241161 Inhibitor / 否
HY-162291 Lck-IN-3 Inhibitor / 否
HY-127002A Squarunkin A hydrochloride Inhibitor / 否
HY-10363 AP 24149 Inhibitor / 否
HY-102073 TG53 Inhibitor / 否
HY-139890 DC-Srci-6649 Inhibitor / 否
HY-13342AS Apatinib-d8 free base 92.56% 否
HY-P1111 Lyn peptide inhibitor Inhibitor / 否
HY-P1784 Secretin, canine / 否
HY-157497 DA5-HTL Inhibitor / 否
HY-101268 CHMFL-ABL-053 Inhibitor / 否
HY-15805 KIN-8194 Inhibitor / 否
HY-110367 LCB 03-0110 dihydrochloride Inhibitor / 否
HY-15814 HG-7-85-01 Inhibitor 99.94% 否
HY-P2547 Tyrosine Kinase Peptide 1 / 否
HY-18507A AD57 hydrochloride Inhibitor / 否
HY-108016 Peruvoside Inhibitor / 否
HY-110367A LCB 03-0110 Inhibitor / 否
HY-P0200 RR-SRC / 否
HY-W744699 Larixol Inhibitor / 否
HY-111187 KX2-361 Inhibitor 99.55% 否
HY-121828 TX-1123 Inhibitor / 否
HY-157290 HL403 Inhibitor / 否
HY-P1200 Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH Inhibitor / 否
HY-15268 PP487 Inhibitor / 否
HY-138202 Lck-IN-1 Inhibitor / 否
HY-157998 mG2N001 / 否
HY-150026 Multi-kinase-IN-2 Inhibitor / 否
HY-147314 HIV-IN-6 98.35% 否
HY-112096S eCF506-d5 Inhibitor / 否
HY-N7160 2-Hydroxy-3-methylanthraquinone Inhibitor / 否
HY-W700620 Hydroxymethyl dasatinib Inhibitor / 否
HY-P1377 Caffeic acid-pYEEIE / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Src NCBI NCBI:6714
Mus musculus Src NCBI NCBI:20779
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z